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Bullous pemphigoid is a subepidermal autoimmune
blistering disease associated with autoantibodies to
the hemidesmosomal bullous pemphigoid antigens
180 and 230. Most sera from bullous pemphigoid
patients recognize epitopes within the N-terminal
NC16A portion of the bullous pemphigoid 180 ecto-
domain. Using cryosections of human skin, patients'
sera were shown to generate dermal±epidermal
separation when coincubated with leukocytes and
complement from healthy volunteers; however, the
speci®city of pathogenic autoantibodies in bullous
pemphigoid patients has not yet been elucidated. In
this study, by the use of a modi®ed version of the
cryosection model, we show that sera from all of 13
bullous pemphigoid patients and from two rabbits,
immunized against bullous pemphigoid 180 NC16A,
induced dermal±epidermal separation. This ®nding
was con®rmed with the use of IgG puri®ed from
patients' sera, whereas sera and puri®ed IgG from
healthy controls were not pathogenic. The induction
of subepidermal splits in this experimental model
was shown to be dependent on the presence of
neutrophils, but not complement. Interestingly,
patients' autoantibodies af®nity puri®ed against a
recombinant form of bullous pemphigoid 180
NC16A retained their blister-inducing capacity,
whereas patients' IgG depleted of reactivity to
NC16A lost this ability. F(ab¢)2 fragments of anti-
bodies speci®c to NC16A, lacking the Fc portion,
did not induce splits. In addition, patients' autoanti-
bodies puri®ed against a recombinant fragment of
the C-terminus of bullous pemphigoid 180 as well as
rabbit antibodies to the intracellular portion of bul-
lous pemphigoid 180 and to bullous pemphigoid 230
did not cause dermal±epidermal separation. Our
in vitro results support the idea that autoantibodies to
bullous pemphigoid 180 from patients with bullous
pemphigoid are of pathogenic relevance. Key
words: autoantigen/autoimmunity/collagen/dermal±epidermal
junction/hemidesmosome. J Invest Dermatol 118:664±671,
2002
B
ullous pemphigoid (BP) is a subepidermal autoimmune
blistering disease of the elderly characterized by tissue-
bound and circulating autoantibodies to the dermal±
epidermal junction (DEJ) (Schmidt and Zillikens,
2000). Autoantibodies in BP are directed to two
hemidesmosomal components, including BP230, an intracellular
constituent of the hemidesmosomal plaque (Stanley et al, 1981,
1988), and the transmembrane protein BP180 (Labib et al, 1986;
Diaz et al, 1990; Giudice et al, 1992). The majority of BP sera react
with epitopes clustered within the 16th noncollagenous (NC16A)
domain of BP180 (Giudice et al, 1993; Zillikens et al, 1997b) and
serum levels of autoantibodies to BP180 NC16A were shown to
parallel disease activity in patients with this disease (Schmidt et al,
2000a).
The pathogenic effect of rabbit antibodies generated against the
murine homolog of BP180 NC16A has previously been demon-
strated in a passive transfer mouse model of BP (Liu et al, 1993). In
addition, the functional relevance of autoantibodies from patients
with BP was recently shown when cultured human keratinocytes,
incubated with IgG from BP patients triggered a signal transduction
event that led to the expression and secretion of interleukins 6 and
8 (Schmidt et al, 2000b); however, the blister-inducing capacity of
human autoantibodies to BP180 has not yet been unequivocally
demonstrated.
Gammon et al (1982a) have previously shown that serum samples
from patients with BP induce dermal±epidermal separation (DES)
in cryosections of human skin when incubated with leukocytes and
complement from healthy donors; however, at the time this
experimental model was developed, tools to characterize the
speci®city of pathogenically relevant autoantibodies in patients' sera
were not available. In this study, we show that IgG antibodies to
human BP180, puri®ed from sera of BP patients and from rabbits
immunized against recombinant human BP180, induce DES in
cryosections of human skin. This effect was shown to be mediated
by binding of autoantibodies to the NC16A domain of human
BP180.
MATERIALS AND METHODS
Patients' sera Serum samples were obtained from 13 BP patients, prior
to the initiation of therapy and from 13 healthy volunteers. All BP
patients were characterized by: (i) blisters on the skin; (ii) subepidermal
blisters by histopathology; (iii) linear deposits of IgG and C3 at the DEJ
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by direct immuno¯uorescence (IF) microscopy; (iv) circulating IgG
autoantibodies that ®xed complement to the epidermal side of 1 M
NaCl-split human skin by indirect IF microscopy; and (v) reactivity to
BP180 NC16A as detected by immunoblot analysis and enzyme-linked
immunosorbent assay. Findings in patients' sera by indirect IF
microscopy on 1 M NaCl-split skin, reactivity with BP180, BP230, and
LAD-1 (as analyzed by immunoblotting of keratinocyte extracts,
conditioned concentrated HaCaT medium, and a recombinant form of
the BP180 C-terminus), and enzyme-linked immunosorbent assay
reactivity against recombinant BP180 NC16A are shown in Table I.
Polyclonal rabbit antibodies to BP180 and BP230 Two rabbit sera,
R2296 and SA8010, were raised against a glutathione-S-transferase fusion
protein containing a 42 amino acid stretch of human BP180 NC16A
(NC16A2±4). Preimmune and anti-GST rabbit serum (Sigma, St Louis,
MO) were used as controls. Rabbit serum SA6760 was generated against
a fusion protein spanning amino acids 61±360 of the intracellular domain
of BP180 (SchaÈcke et al, 1998). Rabbit serum to BP230 was generated
against a 165 kDa recombinant fragment of the C-terminal domain of
BP230 (Tanaka et al, 1990). The characteristics of these antibodies are
shown in Table II.
Preparation of cryosections, indirect IF microscopy, and
complement-®xation test Neonatal human foreskin, obtained from
routine circumcision, was washed in cold phosphate-buffered (PBS), cut
in pieces of 5 3 15 mm, embedded in optimum cutting temperature
compound (Sakura Finetek Europe BV, Zoeterwonde, the Netherlands),
and stored at ±80°C. Four cryosections of 6 mm were placed in the
center of a Superfrost Plus microscope slide (Menzel-GlaÈser,
Braunschweig, Germany) (Gammon et al, 1982). Indirect IF microscopy
on 1 M NaCl-split human skin followed a previous protocol (Zillikens
et al, 1996). The complement-®xation test was performed on
cryosections of human skin (Katz et al, 1976). Bound C3 was visualized
using a ¯uorescein isothiocyanate-labeled goat anti-human C3 antibody
(Kallestad Diagnostics, Austin, TX). For antigen mapping studies, mouse
monoclonal antibodies to human type IV collagen (clone CIV 22,
Sigma), laminin 5 (clone GB3, Loughborough Leicestershire, U.K), and
BP230 (1E5; Hirako et al, 1998) were used.
Af®nity puri®cation of total IgG and IgG speci®c for epitopes on
BP180 IgG from serum samples of patients, rabbits, and controls was
isolated using protein G sepharose fast ¯ow af®nity column
chromatography (Pharmacia AB, Uppsala, Sweden) as reported (Schmidt
et al, 2000b). Antibodies to BP180 were af®nity puri®ed from sera of BP
patients and immunized rabbits using an AminoLink Plus immobilization
kit following the manufacturer's instructions (Pierce, Rockford, IL).
Brie¯y, recombinant GST fusion proteins containing the NC16A2±4
segment or a cocktail of fusion proteins containing NC16A1, NC16A1±
3, and NC16A2±5 fragments (ratio 1:1:3) were covalently coupled to 4%
beaded agarose at pH 10. Similarly, the GST-BP180 4575 representing a
recombinant form of the C-terminus of BP180 was immobilized on the
agarose matrix. Serum samples were incubated with peptide loaded
matrix; antibodies were eluted with 0.1 M glycine buffer (pH 2.5) and
neutralized with Tris±HCl. Eluted antibodies were concentrated under
extensive washing with PBS (pH 7.2) using Ultrafree 15 ®lters
(Millipore, Bradford, MA). After immunoaf®nity puri®cation against
NC16A, total IgG of the ¯ow-through was puri®ed using protein G.
Reactivity of ¯ow-through and eluted fractions was analyzed by indirect
IF microscopy on salt-split skin and by immunoblotting of recombinant
NC16A, GST-BP180 4575 and both full-length and soluble (LAD-1)
keratinocyte-derived BP180. F(ab¢)2 fragments of autoantibodies to
BP180 NC16A were prepared using a standard protocol (Parham, 1983).
The completeness of fragmentation and the reactivity of the F(ab¢)2
preparations was tested by indirect IF microscopy on 1 M salt split-skin
using ¯uorescein isothiocyanate-labeled secondary antibodies speci®c to
Fab (Sigma) and Fc (Serotec Ltd, Oxford, U.K.) portions of IgG,
respectively.
Production of recombinant and cell-derived forms of BP180 GST
fusion proteins containing full-length BP180 NC16A (NC16A1±5)
(Fig 1), various fragments of this domain, including NC16A1, NC16A3,
NC16A2±4, NC16A2±5, and the BP180 4575 C-terminal segment
(Balding et al, 1996), were expressed in Escherichia coli DH5a (Zillikens
et al, 1997b). Fusion proteins were puri®ed by glutathione agarose
af®nity chromatography (Giudice et al, 1993). The soluble ectodomain of
BP180 (LAD-1) and full-length BP180 were prepared from cultured
keratinocytes (Zillikens et al, 1999). Immunoblotting and enzyme-linked
immunosorbent assay using BP180 NC16A were performed as described
(Zillikens et al, 1997a,b).
Peripheral blood leukocytes and complement Peripheral blood
leukocytes from healthy volunteers were isolated by a sedimentation
gradient containing sodium diatrizoate and dextran 500 following the
instructions of the manufacturer (Nycomed, Oslo, Norway). Cells were
harvested, washed twice in RPMI 1640 (Life Technologies, Karlsruhe,
Germany) and resuspended in the same medium at a density of 6 3 107
cells per ml. The cell suspension was kept on ice and cell viability was
tested using trypan blue; preparations with a viability greater than 95%
were used. Serum samples from healthy volunteers served as a source of
human complement (Gammon et al, 1980) and were diluted 2-fold with
RPMI.
Treatment of cryostat sections Sera from BP patients and controls
were heat inactivated for 30 min at 56°C and diluted 5-fold in PBS.
Protein G af®nity puri®ed IgG was diluted in PBS resulting in a ®nal
Table I. Characterization of sera from patients included in
this study
Sera IIF titera BP180b BP230b
NC16A
(ELISA)c LAD-1d 4575e
BP-GC 320 ± ± 0.265 ± ±
BP-ZO 640 + + 0.347 + ±
BP-SA 1280 + ± 0.844 + +
BP-OR 2560 + + 0.592 + ±
BP-KM 320 ± ± 0.791 + ±
BP-CE 320 + ± 0.752 + +
BP-BA 160 ± ± 0.579 + ±
BP-CV 640 ± + 0.283 + ±
BP-BK 1208 + ± 1.070 + ±
BP-RA 640 + ± 0.982 + ±
BP-AM 640 ± + 0.434 ± ±
BP-HU 160 + ± 0.594 + ±
BP-PR 320 + ± 0.200 + +
aTiter of IgG reactivity by indirect immuno¯uorescence (IIF) microscopy on
1 M NaCl-split human skin.
bImmunoblot reactivity with BP180 and BP230 from cellular extracts of cultured
human keratinocytes.
cNumbers indicate the results of the OD492 readings. The cut-off for the en-
zyme-linked immunosorbent assay with recombinant NC16A was set at 0.2.
ELISA, enzyme-linked immunosorbent assay.
dImmunoblot reactivity with the soluble BP180 ectodomain (LAD-1) from con-
centrated conditioned medium of cultured HaCaT cells.
eImmunoblot reactivity with GST-4575 representing a recombinant fragment of
BP180 C-terminus.
Table II. Monoclonal and polyclonal antibodies to BP180 and BP230 included in this study
Designation Species Molecular target IIF titera C3b
SA6760 Rabbit, polyclonal BP180, intracellular domain 1280 ±
SA8010 Rabbit, polyclonal BP180, NC16A domain 640 +
R2296 Rabbit, polyclonal BP180, NC16A domain 2560 +
± Rabbit, polyclonal BP230, C-terminal region 20480 ±
aTiter of indirect immuno¯uorescence microscopy on 1 M NaCl-split human skin.
bLinear deposits of human C3 at the DEJ demonstrated by complement-®xation test.
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concentration of 4 mg per ml. Rabbit antibodies to BP180 and BP230
were used at an indirect IF titer of 320. Cryostat sections were washed
with PBS for 5 min to remove embedding medium before incubation
with 50 ml of diluted sera or antibody preparations for 90 min at room
temperature. After washing the sections with PBS twice, chambers were
prepared as described elsewhere (Gammon et al, 1982a) with minor
modi®cations. Brie¯y, tissue containing slides were covered with a
second slide to which transparent adhesive tape (Beiersdorf AG,
Hamburg, Germany) had been placed around each end. The tape
prevented contact of the skin sections with the covering slide thus
creating a chamber of approximately 0.3 mm in thickness and a volume
of 0.5 ml. Both slides were taped together and the leukocyte suspension,
mixed 1:1 with either diluted fresh or heated serum or medium alone,
was injected into the chambers. Chambers were incubated in a
humidi®ed air incubator containing 5% CO2 (Memmert, Schwabach,
Germany) for 3 h at 37°C. Subsequently, chambers were disassembled
and sections were washed in PBS for 10 min to remove excess serum
and nonadherent cells, air dried for 10 min, ®xed in formalin, and ®nally
stained with hematoxylin and eosin. Sections were examined by two
blinded independent investigators at 350, 3100, and 3200 magni®ca-
tions. As criterion for DES we set the presence of more than three areas
of separation at the DEJ with more than 40 mm in length.
RESULTS
Sera and puri®ed IgG from BP patients recruit neutrophils
to the DEJ and induce subepidermal splits in cryosections of
human skin Serum samples from BP patients (n = 13) labeled
the DEJ when incubated with cryosections of human skin (Fig 2a),
whereas sera from healthy controls (n = 13) showed no binding
(Fig 2d). Incubation of cryosections with serum samples from BP
patients, followed by incubation with complement-containing
serum and leukocytes from healthy volunteers, led to the
attachment of neutrophils to the DEJ, and most importantly, to
the induction of subepidermal splits by all of the 13 BP sera
(Fig 2b; Table III). In contrast, sera from healthy controls did not
induce leukocyte attachment to the DEJ or a subepidermal split
(Fig 2e). When the serum as a source of complement was heat
inactivated or omitted completely, BP sera still induced
subepidermal splits (Fig 2c). Omitting complement, neutrophil
attachment to the stratum corneum, induced by both patients' and
control sera, was abolished (Fig 2c, f ). Using protein G af®nity
puri®ed IgG from four BP patients (Table V) and four healthy
volunteers, we observed the same ®ndings compared with the use
of whole serum. IgG from BP patients, in contrast to controls, led
to neutrophil attachment and induced subepidermal cleavage. No
separation occurred when leukocytes were omitted.
The extent of neutrophil attachment to the DEJ depends on
both the concentration of antibodies to BP180 and the
incubation time with the cells In a further set of experiments,
we investigated the time dependency of neutrophil attachment to
the DEJ incubating the cryosections with three different BP sera
(BP-SA, BP-CE, and BP-HU) for 1, 2, 3, and 4 h, respectively.
Leukocyte attachment to the DEJ was strongest after an incubation
time of 1 h and declined subsequently, whereas the extent of DES
increased after an incubation time of 1 h and reached its maximum
after 3 h (Fig 3). To study the dependency of leukocyte
attachment on levels of autoantibodies to BP180 NC16A, we
puri®ed antibodies speci®c to NC16A from two BP patients (BP-
CE and BP-SA) by immunoaf®nity chromatography. Higher
concentrations of antibodies to NC16A induced stronger
leukocyte attachment compared with incubation with
preparations containing less reactivity to NC16A (Table IV).
Figure 2. Autoantibodies from BP patients
bind to the DEJ and induce subepidermal
splits. Cryosections of human skin that were
incubated with serum from a BP patient (a±c)
show IgG deposits at the DEJ (a). The addition of
normal human leukocytes results in subepidermal
splits both in the presence (b) or absence (c) of
fresh serum as a source of human complement. In
contrast, cryosections incubated with serum from
a healthy control (d±f) do not demonstrate binding
of IgG to the DEJ (d) and reveal no split
formation after incubation with leukocytes
irrespective of addition of complement (e, f). Scale
bar: 40 mm.
Figure 1. Schematic diagram of human BP180. The cytoplasmatic
globular domain of BP180 is shown at the top. The transmembrane
region of BP180 is labeled TM. The ectodomain consists of 15
interrupted collagen domains (bright boxes) and forms a central rod that
spans the lamina lucida (LL); the carboxy terminal ¯exible tail protrudes
into the lamina lucida (LL)/lamina densa (LD) interface (Nonaka et al,
2000). The recombinant forms of the NC16A domain are depicted to
the left. Amino acid residue numbers are shown next to the boxes. The
NC16A domain has been subdivided into ®ve regions, each of
approximately 15 amino acids in length.
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Splits induced experimentally by autoantibodies from BP
patients localize to the lamina lucida of the DEJ To study
the level of split formation, we stained cryosections, that had
previously been incubated with sera from BP patients and
leukocytes, with monoclonal antibodies to human BP230 (1E5),
type IV collagen, and laminin 5. Antibodies to BP230 stained the
roof of the split, whereas those to both type IV collagen and
laminin 5 labeled the dermal side demonstrating that the level of
split formation localizes to the lamina lucida of the DEJ.
Immunoadsorption against recombinant BP180 NC16A
abolishes the capacity of BP patients' sera to induce
DES Sera from two BP patients (BP-SA and BP-CE) were
subjected to af®nity puri®cation using a cocktail of recombinant
fragments covering the entire NC16A domain of BP180 that was
covalently coupled to an agarose matrix. Total IgG from ¯ow-
through fractions was isolated by protein G chromatography and
concentrated to the same volume as the eluted fraction. The eluted
IgG strongly reacted with recombinant NC16A by immunoblot
analysis. In contrast, IgG from ¯ow-through fractions showed no
reactivity with NC16A demonstrating the complete elimination of
antibodies to this portion of BP180 (Fig 4). Subsequently, IgG
speci®c for BP180 NC16A and ¯ow-through fractions were tested
by indirect IF microscopy on 1 M NaCl-split skin. Interestingly,
both eluted and ¯ow-through fractions still contained IgG that
bound to the epidermal side of the split (Table V). When
concentrated to the same volume, indirect IF titers of ¯ow-through
fractions were 2-fold lower compared with the eluted fractions.
Both eluted and ¯ow-through fractions also reacted with cell-
derived full-length BP180 and LAD-1 (Fig 4) indicating that the
immunoadsorption procedure only abolished antibodies to NC16A
from the sera, whereas IgG directed to other autoantigens or to
other portions of the BP180 molecule remained unaffected.
Importantly, IgG speci®c to the NC16A domain of BP180
induced subepidermal splits in the cryosections (Fig 5c), whereas
the ¯ow-through fractions of BP sera lost their blister-inducing
capacity (Fig 5d). When we concentrated the IgG from ¯ow-
through fractions to an indirect IF titer 2-fold higher compared
with the eluted fraction, these preparations still did not induce
leukocyte attachment to the DEJ or subepidermal cleavage. Under
these conditions, the IgG concentration of the ¯ow fraction was
80-fold (BP-SA) and 280-fold (BP-CE) higher, respectively,
compared with the eluted fraction and the IgG preparations had
the same complement-®xing ability. In a further set of experiments,
we puri®ed antibodies speci®c to the C-terminus of BP180 from
serum of three BP patients (BP-CE, BP-SA, and BP-PR) using
Figure 3. Attachment of leukocytes to the
DEJ is strongest after short incubation times,
whereas DES is more extensive with longer
incubation. In the upper panel, cryosections
were incubated with serum from BP-SA followed
by incubation with leukocytes for 1, 2, and 3 h,
respectively. Scale bar: 40 mm. The lower panel
shows the extent of leukocyte attachment and
DES after incubating the cryosections with three
BP sera (BP-SA, BP-CE, and BP-HU). The mean
values of percent of the total length of DEJ with
attached leukocytes (r) or DES (j) are
demonstrated at incubation times of 1, 2, 3, and
4 h, respectively. The individual readings with the
three different sera are also shown (leukocyte
attachment, s; DES, +).
Table III. The role of autoantibodies, complement, and




BPS + complementd ± ± ±
NHS + complement ± ± ±
BPS + complement + leukocytes + + +







BPS + leukocytes + ± +
NHS + leukocytes ± ± ±
aLeukocyte attachment to the DEJ.
bLeukocyte attachment to the stratum corneum (SC).
cDermal±epidermal separation.
dFresh serum from healthy donors was used as a source of complement.
eComplement was inactivated by heating the serum from healthy donors for
30 min at 56°C.
BPS, bullous pemphigoid serum; NHS, normal human serum.
Table IV. Neutrophil attachment to the DEJ increases with








aAntibodies speci®c to NC16A were isolated from the serum of two patients
(BP-SA, BP-CE) by immunoaf®nity column chromatography and incubated with
cryosections of human skin followed by a 2 h incubation with human leukocytes.
bTiter of antibodies puri®ed against BP180 NC16A by indirect IF microscopy
on 1 M NaCl-split human skin.
cLength of DEJ with attached leukocytes in relation to total length (percent).
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recombinant GST-BP180 4575. Antibody preparations to this
fragment of BP180, which strongly ®xed complement, were
concentrated to a titer of 80 (Table V). While at this titer, patient
antibodies speci®c to NC16A induced DES, antibodies speci®c to
the BP180 C-terminus induced no leukocyte attachment and no
DES.
F(ab¢)2 fragments of autoantibodies to NC16A do not induce
subepidermal cleavage in cryosections of human skin To
address the question, if the Fc portion of autoantibodies is of
importance for blister induction in our in vitro model, we prepared
F(ab¢)2 fragments of antibodies that had been eluted from NC16A
coupled to agarose. IgG speci®c to NC16A from two BP patients
(BP-SA and BP-CE) was digested with pepsin. F(ab¢)2 fragments,
lacking the Fc portion of the antibody, were used at the same
indirect IF titer (80) as the original unfragmented antibody
preparations to BP180 NC16A that were pathogenic; however,
F(ab¢)2 preparations did not induce subepidermal cleavage when
incubated with the cryosections.
IgG from rabbits immunized against recombinant human
BP180 NC16A induce subepidermal splits in skin cryo-
sections For this study, we immunized two rabbits (R2296 and
SA8010) against recombinant NC16A2±4. When cryosections
Figure 4. Immunoblot analysis using IgG
from BP sera af®nity puri®ed against BP180
NC16A Puri®cation of autoantibodies to BP180
NC16A1±5 from two BP sera (BP-SA and BP-
CE) was performed using an agarose beaded gel
covalently coupled with a cocktail consisting of
NC16A1, NC16A1±3, and NC16A2±5
encompassing the entire NC16A domain. Left
panel, immunoblotting of recombinant BP180
NC16A with BP-SA (lanes 1±3) and BP-CE (lanes
4±6). IgG autoantibodies eluted from the column
(lanes 3 and 6) react, like reference control serum
BP-CO (lane 7), with NC16A, whereas ¯ow-
through fractions (lanes 2 and 5) or normal serum
(lane 8) show no reactivity. Right panel,
Immunoblotting of keratinocyte-derived full-
length BP180. Serum samples from BP-SA and
BP-CE (lanes 1 and 4), eluted fractions (lanes 3
and 6), but also IgG in ¯ow-through fractions
(lanes 2 and 5) react with full-length BP180
(arrow). Reactivity of control sera (BP-CO and
NHS) is shown in lanes 7 and 8. Migration
position of molecular weight markers are depicted
on the left and right.
Table V. Characterization of af®nity puri®ed immunoglobulin preparations used in this study
Sera Fraction
Puri®cation with protein Ga
Concentrationb
(mg per ml) IIF titerc
BP-GC Total IgG 49 5120
BP-OR Total IgG 78 10240
BP-KM Total IgG 38 1280
BP-PR Total IgG 13 640
Immunoaf®nity puri®cation against epitopes of BP180
NC16Ad C-terminuse
Concentration
(mg per ml) IIF titer
Concentration
(mg per ml) IIF titer
BP-SA EF 0.3 80 BP-SA EF 0.35 80
FTF 13.2 80 FTF 80
BP-CE EF 0.21 80 BP-CE EF 0.4 80
FTF 28 80 FTF 80
R-SA8010 EF 4 320 BP-PR EF 0.3 80
FTF 0 FTF 80
aTotal IgG fractions were isolated from human sera using protein G af®nity column chromatography (stock preparations).
bConcentrations of af®nity puri®ed antibodies were determined using Bradford protein assay.
cAntibody titer by indirect IF microscopy on 1 M NaCl-split human skin.
dAntibodies to BP180 NC16A from patients' and rabbit sera were af®nity puri®ed against recombinant NC16A fragments covalently coupled to an agarose matrix.
eAntibodies to C-terminal BP180 from patients' sera were af®nity puri®ed against the recombinant 4575 fragment covalently coupled to an agarose matrix.
EF, eluted fraction; FTF, ¯ow-through fraction.
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were incubated with sera SA8010 and R2296 or with IgG from
SA8010, af®nity puri®ed against BP180 NC16A2±4, and
subsequently treated with leukocytes from healthy donors, a
subepidermal split formation was observed (Fig 5a). In contrast,
preimmune rabbit sera, serum from a rabbit immunized against
recombinant GST, and the ¯ow-through fraction of serum
SA8010, obtained after subjecting the serum to af®nity
puri®cation with recombinant NC16A2±4, did not bind to the
DEJ and did not induce DES in the cryosections (Fig 5b).
Although used at the same indirect IF titers as rabbit antibodies to
NC16A (320), rabbit antibody SA6760 to the intracellular domain
of BP180 and a rabbit antibody to BP230 were not pathogenic in
this model.
DISCUSSION
In this study, we show the capacity of antibodies to human BP180
from patients with BP and from rabbits immunized with
recombinant BP180 to induce subepidermal splits. This study
used, with some modi®cations, an in vitro model originally
described by Gammon et al (1982a) involving cryosections of
human skin, sera from BP patients, and leukocytes; however, at the
time their model was ®rst reported, the different speci®cities of
autoantibodies in BP sera had not been elucidated. Subsequent
work demonstrated that autoantibodies in BP sera are directed to
two major autoantigens, BP180 and BP230 (Stanley et al, 1981,
1988; Labib et al, 1986; Diaz et al, 1990).
Previous attempts to induce BP by passive transfer of patients'
autoantibodies into different animals had failed (Sams and Gleich,
1971; Gammon and Briggaman, 1988). The pathogenic relevance
of BP180 was strongly suggested by the use of an animal model
where neonatal mice injected with rabbit anti-murine BP180
antibodies developed a BP-like subepidermal blistering disease (Liu
et al, 1993); however, the pathogenic effect of antibodies to BP180
from patients with BP has not been demonstrated to date.
Recently, we also failed to induce blisters by injection of
autoantibodies to BP180 from patients with BP into human skin
grafted on to severe combined immunode®cient mice (Zillikens et
al, 2001).
In this study, we therefore used the cryosection model to test the
hypothesis that antibodies to human BP180 are pathogenic. In a
®rst set of experiments, we reproduced the ®nding of Gammon et al
(1982a) that sera from BP patients induce subepidermal splits in
cryosections of human skin. Subsequently, this observation was
con®rmed with the use of IgG fractions isolated by protein G
af®nity puri®cation from BP patients, whereas normal human sera
or normal IgG caused no DES. The level of experimentally induced
split formation localizes to the lamina lucida of the DEJ, the same
site where blister formation occurs in the patient's skin (Schmidt
and Zillikens, 2000). Interestingly, omission of complement did not
change the extent of DES in our assay. Gammon et al (1982a) had
also found some degree of DES in cryosections treated with heat-
inactivated serum. Their three-step skin chamber method consisted
of incubation with BP sera (step 1), followed by leukocytes (step 2),
and ®nally by fresh serum as a source of complement (step 3).
Importantly, in their assay, the incubation with leukocytes was
performed prior to the addition of complement. In addition, to
remove nonadherent leukocytes the sections were then rinsed in
PBS before complement was added. This sequence of incubation
steps could not undoubtedly clarify the role of complement for the
induction of splits in the assay described by Gammon et al (1982a);
however, from these and our own data one may not conclude that
complement activation is not essential for blister formation in BP.
In the cryosection model, in contrast to the in vivo situation, the
leukocytes do not have to migrate along a chemotactic gradient
from blood vessels to the DEJ. Instead, by incubating the
cryosections with leukocytes, the cells are placed in close contact
with the DEJ. As in the cryosection model there is no requirement
for complement to induce splits, the role of complement in blister
formation of human BP cannot be explored in this in vitro model
and will be addressed in future studies using other experimental
models. On the other hand, our data clearly show the importance
of neutrophils for the induction of DES in the cryosection model:
(i) omitting leukocytes resulted in a lack of split formation, and (ii)
pepsin digestion of split-inducing autoantibodies, which leads to a
loss of the Fc portion (mediating binding of neutrophils to immune
complexes), also abolished split formation.
In a second set of our experiments, we studied the time-
dependency of leukocyte attachment and split formation in our
assay. We demonstrate that leukocyte attachment to the DEJ
predominates over DES with shorter incubation times (1 h) and
declines with longer incubation, whereas the extent of DES
increases gradually and reaches its maximum with longer incuba-
tion (3 h). When fresh serum was added as a source of complement,
we regularly found attachment of neutrophils to the stratum
corneum of the cryosections irrespective of whether the sections
were incubated with sera/puri®ed IgG from patients or controls.
This observation is in line with the ®nding that corneocytes may
Figure 5. Antibodies to BP180 NC16A
induce subepidermal splits in cryosections of
human skin. Serum from rabbit SA8010,
immunized against recombinant human GST-
NC16A2±4 (a), and autoantibodies from patient
BP-SA, af®nity puri®ed against BP180 NC16A
(c), induce DES in cryosections of human skin
when coincubated with leukocytes from healthy
donors. In contrast, incubation with serum from a
rabbit immunized against GST (b) or the ¯ow-
through fraction of serum BP-SA (d) do not lead
to split formation. Scale bar: 40 mm.
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activate the alternative complement pathway thus mediating the
adhesion of leukocytes to serum-treated stratum corneum in an
antibody-independent manner (Terui et al, 1989; Terui et al, 1995).
When fresh serum was omitted or replaced by heat-inactivated
serum, we did not observe a major neutrophil adhesion to the
stratum corneum.
The importance of antibodies to the NC16A domain of BP180
has been suggested by several lines of evidence: (i) in experimental
murine BP, antibodies to the murine homolog of human NC16A
induce skin blisters in neonatal mice (Liu et al, 1993, 1995); (ii) in
BP patients, serum levels of circulating antibodies to NC16A, in
contrast to indirect IF microscopy titers of antibodies to the DEJ,
correlate with disease activity (Schmidt et al, 2000a); and (iii)
antibodies to the NC16A domain were identi®ed to trigger
expression and secretion of in¯ammatory mediators when incu-
bated with cultured normal human keratinocytes (Schmidt et al,
2000b). In a further set of experiments, we therefore tested the
pathogenic relevance of antibodies to BP180 NC16A from BP
patients in cryosections of human skin. Interestingly, when we
af®nity puri®ed antibodies speci®c to BP180 NC16A from the
serum of BP patients, this fraction induced a concentration-
dependent leukocyte attachment to the DEJ, and subsequently
subepidermal splits in the cryosections. The split-inducing potential
of autoantibodies speci®c to BP180 NC16A was shown to be
dependent on their Fc portion. In contrast, serum fractions that
were depleted of reactivity BP180 NC16A (¯ow-through fractions)
lost their split-inducing capacity, although they remained reactive
with full-length BP180 and LAD-1 derived from cultured
keratinocytes. Autoantibodies from BP patients, puri®ed against
the C-terminus of BP180, and used at the same indirect IF titer and
IgG concentration as antibodies to NC16A, were also not
pathogenic. These data suggest that the split-inducing ability of
autoantibodies is associated with their speci®city. This is further
supported by ®ndings using the experimental mouse model of BP.
By molecular mapping studies it was shown that the blister-
inducing ability of rabbit antibodies generated to different
recombinant forms of murine BP180 was dependent on their ®ne
speci®city (Liu et al, 1995). Evidence that speci®city of antibodies
may be associated with their pathogenicity is also provided by
studies using a mouse model for hemolytic anemia where mice
develop autoantibodies to different membrane antigens on
erythrocytes. An analysis of autoantibodies and of a panel of anti-
red blood cell monoclonal antibodies derived from the diseased
mice revealed that pathogenic and nonpathogenic autoantibodies
differed with regard to their speci®city (DeHeer et al, 1978; Shibata
et al, 1990; Diiulio et al, 1997). In these mice, anemia was shown to
be mediated by Fc receptor-dependent erythrophagocytosis
(Shibata et al, 1990; Clynes and Ravetch, 1995).
In a ®nal set of experiments, the pathogenic relevance of
antibodies to the NC16A domain was further con®rmed by the
®nding that treatment of cryosections of human skin with rabbit
sera generated against BP180 NC16A2±4 also resulted in
subepidermal splits. No split was induced when rabbit serum was
depleted of reactivity against NC16A2±4 by af®nity chromato-
graphy or when cryosections were incubated with preimmune
rabbit sera. Interestingly, although used at the same indirect IF titers
as rabbit antibodies to NC16A, rabbit antibodies to the intracellular
domain of BP180 did not induce subepidermal splits when
incubated with the cryosections, nor did rabbit antibodies to
BP230.
In summary, this study demonstrates that antibodies to human
BP180, in the presence of leukocytes, induce subepidermal splits in
cryosections of human skin, which con®rms that BP180 plays a key
part in the pathogenesis of BP. We show that the pathogenic
mechanisms that lead to subepidermal split formation are mediated
by autoantibodies targeting epitopes within the NC16A domain of
BP180. Future studies will be aimed at characterizing the
pathogenically relevant epitope(s) within NC16A and other
potentially relevant epitopes on the BP180 molecule.
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